Business
The company gained Karuna’s team, customers, technology and insights through the deal.
This Series C comes less than a year after the startup closed its $200 million Series B in 2020.
The company boasted strong revenues and membership growth but took a hit in its GAAP net income.
The acquisition allows cliexa to meet GI customers with an end-to-end automated scheduling, reporting and communications platform.
The company currently has 11 locations delivering virtual-supported care, but now plans to open "several" more in the first half of 2021.
This merger comes over a year after news broke that Outcome Health faced a number of legal battles.
The company's technology looks to reduce the burden on pathologists reviewing digital slides, while also serving as a safety net to reduce errors.
The deal is expected to close in the second quarter of 2021. It will value the combined company at approximately $1.1 billion.
Also: Valo Health closes $300 million for machine learning drug discovery; Blue Note Therapeutics supports its in-development prescription DTx with $26.25 million.
According to Business Insider, the pair made a $70 million licensing deal.